#1 Clinical Trials Search in Europe

Clopidogrel Hydrogen Sulfate

This article explores the use of Clopidogrel Hydrogen Sulfate in various clinical trials. Clopidogrel is an antiplatelet medication commonly used in patients with coronary artery disease, especially those undergoing procedures like percutaneous coronary intervention (PCI). The trials discussed here investigate different dosing regimens, their effects on platelet function, and potential outcomes in patients with heart conditions. These studies aim to optimize the use of clopidogrel to improve patient care and reduce complications associated with heart procedures.

Table of Contents

What is Clopidogrel?

Clopidogrel hydrogen sulfate, commonly known as clopidogrel, is an important medication used in the treatment of cardiovascular conditions. It belongs to a class of drugs called thienopyridines[1]. Clopidogrel is also known by other names, including SR25990[2]. This medication is primarily used to prevent blood clots in patients with certain heart and blood vessel conditions.

Medical Uses

Clopidogrel is prescribed for several cardiovascular conditions, including:

  • Coronary Artery Disease (CAD): This is a condition where the arteries supplying blood to the heart become narrowed or blocked[3].
  • Acute Coronary Syndromes (ACS): This includes conditions like unstable angina and heart attacks[1].
  • After Percutaneous Coronary Intervention (PCI): PCI, also known as angioplasty, is a procedure to open blocked coronary arteries. Clopidogrel is often prescribed after this procedure to prevent blood clots from forming in the newly opened artery[4].
  • Myocardial Ischemia: This condition occurs when blood flow to the heart is reduced, preventing it from receiving enough oxygen[4].

How Clopidogrel Works

Clopidogrel is an antiplatelet medication. It works by preventing platelets (small blood cells) from sticking together and forming clots[1]. When you take clopidogrel, it is converted in your body into an active form that permanently blocks a specific receptor on platelets. This action reduces the risk of blood clots forming in your arteries, which can lead to serious events like heart attacks or strokes.

Dosage and Administration

The dosage of clopidogrel can vary depending on the specific condition being treated and individual patient factors. Common dosing regimens include:

  • Loading dose: A higher initial dose, often 300 mg or 600 mg, given to quickly achieve an effective level of the drug in the body[5].
  • Maintenance dose: A lower daily dose, typically 75 mg or 150 mg, taken to maintain the drug’s effect over time[5].

Clopidogrel is usually taken orally in tablet form. It’s often prescribed alongside aspirin as part of a dual antiplatelet therapy[4].

Effectiveness and Individual Variability

The effectiveness of clopidogrel can vary from person to person. Some individuals may have a reduced response to the medication, which is known as clopidogrel resistance[5]. This variability can be due to genetic factors, particularly variations in the CYP2C19 gene, which is involved in converting clopidogrel to its active form[2].

To address this variability, doctors may use tests to measure how well clopidogrel is inhibiting platelet function in individual patients. Based on these results, they might adjust the dosage or consider alternative medications[1].

Side Effects and Risks

While clopidogrel is generally well-tolerated, it can cause side effects. The most significant risk is bleeding, as the medication reduces the blood’s ability to clot. Potential side effects and risks include:

  • Bleeding complications: This can range from minor bruising to more serious internal bleeding[5].
  • Gastrointestinal issues: Such as stomach pain or discomfort.
  • Allergic reactions: In rare cases, some people may experience an allergic reaction to the medication.

It’s important to discuss any side effects with your healthcare provider and to inform them of all other medications you’re taking, as clopidogrel can interact with other drugs.

Ongoing Research

Research on clopidogrel is ongoing, with studies focusing on optimizing its use in different patient populations. Some areas of current research include:

  • Evaluating different dosing regimens to improve effectiveness and reduce side effects[3].
  • Investigating the impact of genetic factors on clopidogrel response[2].
  • Comparing clopidogrel to newer antiplatelet medications[1].
  • Studying the long-term outcomes of clopidogrel use in various cardiovascular conditions[4].
Aspect Details
Primary Focus Evaluating different dosing regimens of Clopidogrel Hydrogen Sulfate
Key Conditions Studied Coronary Artery Disease, Myocardial Ischemia
Main Procedures Percutaneous Coronary Intervention (PCI), Coronary Stent Implantation
Dosing Regimens Explored Various combinations of loading doses (300mg, 600mg) and maintenance doses (75mg, 150mg)
Primary Outcomes Measured Inhibition of platelet aggregation, cardiovascular events (death, myocardial infarction, stroke)
Secondary Outcomes Stent thrombosis, bleeding complications, pharmacokinetic parameters
Special Considerations Genetic variations affecting clopidogrel metabolism, differences in Japanese patient responses
Duration of Studies Ranging from immediate effects to 1 year follow-up

FAQ

  • What is Clopidogrel Hydrogen Sulfate used for? Clopidogrel Hydrogen Sulfate is an antiplatelet medication used primarily in patients with coronary artery disease. It helps prevent blood clots and is often prescribed before and after procedures like percutaneous coronary intervention (PCI) or stent placement.
  • Why are different dosing regimens of clopidogrel being studied? Different dosing regimens are being studied to find the optimal balance between effectiveness in preventing blood clots and minimizing side effects. Researchers are exploring various loading doses and maintenance doses to determine which regimen provides the best platelet inhibition and clinical outcomes.
  • What is platelet aggregation and why is it important in these trials? Platelet aggregation is the clumping together of platelets in the blood, which can lead to clot formation. In these trials, researchers measure the inhibition of platelet aggregation to assess how well clopidogrel is working. Better inhibition of platelet aggregation may lead to reduced risk of complications like stent thrombosis.
  • Are there differences in how people respond to clopidogrel? Yes, studies have shown that there is interindividual variability in response to clopidogrel. Some people, including many Japanese patients, may be 'non-responders' or 'hypo-responders' to standard doses of clopidogrel, which is why researchers are exploring higher doses in some trials.
  • What are some of the outcomes being measured in these clinical trials? The trials are measuring various outcomes, including the degree of platelet inhibition at different time points, occurrence of major cardiovascular events (like heart attack or stroke), stent thrombosis, and bleeding complications. These measurements help researchers understand both the effectiveness and safety of different clopidogrel regimens.

Ongoing Clinical Trials on Clopidogrel Hydrogen Sulfate

  • Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Clopidogrel Hydrogen Sulfate: An antiplatelet medication used to prevent blood clots in patients with heart conditions, particularly those undergoing procedures like stent placement.
  • Percutaneous Coronary Intervention (PCI): A non-surgical procedure used to open blocked coronary arteries and restore blood flow to the heart muscle.
  • Platelet Aggregation: The clumping together of platelets in the blood, which can lead to clot formation. Clopidogrel works by inhibiting this process.
  • Loading Dose: A higher initial dose of medication given to quickly achieve the desired therapeutic effect. In these trials, loading doses of 300mg or 600mg of clopidogrel are being studied.
  • Maintenance Dose: The regular dose of medication taken to maintain its therapeutic effect over time. In these trials, maintenance doses of 75mg or 150mg of clopidogrel are being studied.
  • Stent Thrombosis: A serious complication where a blood clot forms on a coronary stent, potentially blocking blood flow to the heart.
  • Myocardial Infarction: Commonly known as a heart attack, it occurs when blood flow to part of the heart is blocked, causing damage to the heart muscle.
  • Dual Antiplatelet Therapy: The use of two antiplatelet medications, typically aspirin and a drug like clopidogrel, to prevent blood clots after stent placement or in patients with acute coronary syndromes.
  • Genotyping: The process of determining differences in the genetic makeup of an individual. In some trials, genotyping is used to study how genetic variations affect response to clopidogrel.
  • VerifyNow: A device used to measure platelet function and monitor the effectiveness of antiplatelet medications like clopidogrel.

References

  1. https://clinicaltrials.gov/study/NCT01505790
  2. https://clinicaltrials.gov/study/NCT01123824
  3. https://clinicaltrials.gov/study/NCT00693069
  4. https://clinicaltrials.gov/study/NCT02707445
  5. https://clinicaltrials.gov/study/NCT01069302